Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442168 versus placebo in nonrelapsing secondary progressive multiple sclerosis
NL-OMON54474Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing SAR442168 with Placebo (2 arms). Primary endpoint: Time to 6-month confirmed disability progression. Started Jun 2021; status: completed.
02
Drugs
tolebrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON54474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54474.